TY - JOUR
T1 - Clinical features and visual outcomes of ocular sarcoidosis at a tertiary referral center in Tokyo
AU - Nagahori, Katsuya
AU - Keino, Hiroshi
AU - Nakayama, Makiko
AU - Watanabe, Takayo
AU - Ando, Yoshimasa
AU - Hayashi, Isami
AU - Abe, Shinya
AU - Okada, Annabelle A.
N1 - Funding Information:
HK: research funds from Mitsubishi Tanabe Pharma (Japan), lecture fees from Nikon (Japan), Kowa (Japan), Novartis Pharma (Japan), Mitsubishi Tanabe Pharma (Japan), Carl Zeiss Meditec (Germany), Santen Pharmaceutical (Japan), Bayer (Japan) and Senju Pharmaceutical (Japan). AAO: research funds from Bayer (Japan) and Alcon (Japan); consultant fees from Bayer (Japan and Germany), Chugai Pharmaceutical (Japan), Novartis (Japan and Switzerland), Hoya (Japan), Daiichi Sankyo (Japan), Astellas (Japan); lecture fees from Novartis (Japan), Bayer (Japan and Australia), Pfizer (Japan), Santen (Japan), Mitsubishi Tanabe Pharma (Japan), Allergan (Japan), Senju (Japan), Abbvie (Japan), Otsuka Pharmaceutical (Japan).
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2022/10
Y1 - 2022/10
N2 - Background: To analyze clinical features, treatment, complications, and visual outcomes of ocular sarcoidosis at a tertiary center in Tokyo. Methods: Clinical records of 53 patients with ocular sarcoidosis (“definite” or “presumed”) presenting between 2013 and 2018 to the Kyorin Eye Center were retrospectively reviewed. Diagnosis was based on the revised criteria of the International Workshop on Ocular Sarcoidosis. Results: Definite (biopsy-proven) disease was present in 87% of patients and presumed disease in 13%. The mean age at presentation was 58 years (13–81 years) and 68% were women. The mean follow-up was 34 months (6–70 months). Forty-five patients (85%) had panuveitis, and the most common ocular clinical sign suggestive of ocular sarcoidosis was bilaterality (92%). Ocular complications were observed in 93 eyes (85%), most commonly cataract (73%), epiretinal membrane (24%), macular edema (24%) and glaucoma (19%). Thirty-one eyes (30%) underwent cataract surgery and 12 eyes (12%) underwent pars plana vitrectomy. Ten patients (19%) received systemic corticosteroid therapy and 33 eyes (32%) received periocular corticosteroid injections. The best-corrected visual acuity was 1.0 or better in 51% of eyes at presentation, 57% at 6 months, 50% at 12 months, and 58% at 36 months. Conclusions: The majority of ocular sarcoidosis patients were women, had bilateral disease and panuveitis involvement. Most eyes maintained good visual acuity, although surgical interventions for cataract and epiretinal membrane were common.
AB - Background: To analyze clinical features, treatment, complications, and visual outcomes of ocular sarcoidosis at a tertiary center in Tokyo. Methods: Clinical records of 53 patients with ocular sarcoidosis (“definite” or “presumed”) presenting between 2013 and 2018 to the Kyorin Eye Center were retrospectively reviewed. Diagnosis was based on the revised criteria of the International Workshop on Ocular Sarcoidosis. Results: Definite (biopsy-proven) disease was present in 87% of patients and presumed disease in 13%. The mean age at presentation was 58 years (13–81 years) and 68% were women. The mean follow-up was 34 months (6–70 months). Forty-five patients (85%) had panuveitis, and the most common ocular clinical sign suggestive of ocular sarcoidosis was bilaterality (92%). Ocular complications were observed in 93 eyes (85%), most commonly cataract (73%), epiretinal membrane (24%), macular edema (24%) and glaucoma (19%). Thirty-one eyes (30%) underwent cataract surgery and 12 eyes (12%) underwent pars plana vitrectomy. Ten patients (19%) received systemic corticosteroid therapy and 33 eyes (32%) received periocular corticosteroid injections. The best-corrected visual acuity was 1.0 or better in 51% of eyes at presentation, 57% at 6 months, 50% at 12 months, and 58% at 36 months. Conclusions: The majority of ocular sarcoidosis patients were women, had bilateral disease and panuveitis involvement. Most eyes maintained good visual acuity, although surgical interventions for cataract and epiretinal membrane were common.
KW - Sarcoidosis
KW - Uveitis
KW - Visual prognosis
UR - http://www.scopus.com/inward/record.url?scp=85131011123&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131011123&partnerID=8YFLogxK
U2 - 10.1007/s00417-022-05701-x
DO - 10.1007/s00417-022-05701-x
M3 - Article
C2 - 35616725
AN - SCOPUS:85131011123
SN - 0721-832X
VL - 260
SP - 3357
EP - 3363
JO - Graefe's Archive for Clinical and Experimental Ophthalmology
JF - Graefe's Archive for Clinical and Experimental Ophthalmology
IS - 10
ER -